Embecta showcases its insulin patch pump at ADA

Embecta has submitted an open-loop version of its first patch pump to the FDA and is developing a closed-loop version. At the American Diabetes Association Scientific Sessions, the company presented abstracts supporting its insulin patch pump for Type 2 diabetes, submitted for FDA clearance in late 2023.

The patch pump has a larger insulin reservoir of 300 units, compared to Insulet’s Omnipod 5's 200 units. Other companies like Tandem Diabetes Care and Medtronic are also developing patch pumps.

Embecta, known for pen needles and insulin syringes, found that a larger reservoir could extend wear times and reduce disposable patches. One study showed that the average daily insulin dose for over 41,000 adults with Type 2 diabetes on multiple daily injections was 96 units.

A 300-unit reservoir would meet the needs of 64% of adults for 72 hours, while a 200-unit reservoir would suffice for 38%. Embecta has not announced a sales date for the device.